GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
50.21
-51.32 (-50.55%)
At close: Feb 20, 2026, 4:00 PM EST
49.39
-0.82 (-1.63%)
After-hours: Feb 20, 2026, 7:59 PM EST
GRAIL Employees
GRAIL had 1,000 employees as of December 31, 2024. The number of employees decreased by 360 or -26.47% compared to the previous year.
Employees
1,000
Change
-360
Growth
-26.47%
Revenue / Employee
$147,172
Profits / Employee
-$408,351
Market Cap
2.03B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 1,000 | -360 | -26.47% |
| Sep 30, 2024 | 1,170 | -190 | -13.97% |
| Dec 31, 2023 | 1,360 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| RadNet | 9,000 |
| Sotera Health Company | 3,000 |
| OPKO Health | 2,997 |
| Neogen | 2,974 |
| NeoGenomics | 2,500 |
| GeneDx Holdings | 1,000 |
| Twist Bioscience | 979 |
| Veracyte | 824 |
GRAL News
- 22 hours ago - This once-hot cancer-detection company's stock got cut in half after a failed trial - Market Watch
- 1 day ago - Grail shares plunge after major cancer screening trial misses main goal - Reuters
- 1 day ago - Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. - Barrons
- 1 day ago - Grail Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses - Business Wire
- 1 day ago - GRAIL, Inc. (GRAL) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire
- 1 day ago - Landmark NHS-Galleri Trial Demonstrates a Substantial Reduction in Stage IV Cancer Diagnoses, Increased Stage I and II Detection of Deadly Cancers, and Four-Fold Higher Cancer Detection Rate - PRNewsWire
- 5 days ago - GRAIL to Announce Fourth Quarter and Full Year 2025 Financial Results - PRNewsWire